Business context and reporting period
The filing is Galena Biopharma, Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2012. The supplied metadata names SELLAS Life Sciences Group, Inc., but the filing itself identifies Galena Biopharma as the registrant.
Galena was a development-stage biopharmaceutical company with no product revenue. Its lead candidate, NeuVax, was in a Phase 3 breast cancer trial; NeuVax with Herceptin was in Phase 2, and its folate-binding-protein vaccine was in Phase 1/2. Galena completed a partial spin-off of RXi in April 2012.
Financial performance and position
Amounts below are in millions of dollars except per-share data. Revenue and operating margins are not applicable: the company reported no revenue.
| Metric | Q3 2012 | Q3 2011 | Nine months 2012 | Nine months 2011 |
|---|---|---|---|---|
| Research and development expense | 4.169 | 1.367 | 10.553 | 1.757 |
| General and administrative expense | 1.359 | 2.068 | 5.068 | 7.136 |
| Operating loss | (5.528) | (3.435) | (15.621) | (8.893) |
| Net loss | (6.261) | (5.475) | (31.218) | (13.074) |
| Net loss per share | (0.09) | (0.13) | (0.52) | (0.39) |
| Cash used in operating activities | — | — | (15.795) | (10.499) |
- At September 30, cash and cash equivalents were $15.423 million, restricted cash $0.101 million, current assets $16.325 million, and current liabilities $10.057 million. Working capital was approximately $6.268 million.
- Total liabilities were $21.027 million. Capital lease obligations totaled approximately $0.057 million; no convertible notes were shown as outstanding at quarter-end.
- Other significant liabilities included $4.904 million for warrants potentially settleable in cash and $6.791 million of contingent NeuVax acquisition consideration, of which $0.925 million was current.
- For the nine months, financing activities provided $19.872 million, including $13.937 million net proceeds from an April stock offering and $5.672 million from warrant exercises.
Changes versus the prior comparable period
- Net loss increased 14% in Q3 and 139% for the first nine months. Nine-month operating cash use rose by $5.296 million.
- R&D expense rose 205% in Q3 and 501% year to date, primarily as the Phase 3 PRESENT trial ramped up.
- G&A expense declined 34% in Q3 and 29% year to date, mainly reflecting lower personnel, professional-services, and employee stock-compensation costs.
- Nine-month other expense was $13.918 million, compared with $1.723 million of other income in 2011. The 2012 expense was primarily non-cash fair-value increases of $11.899 million for warrant liabilities and $2.019 million for contingent purchase consideration.
- Discontinued operations contributed no Q3 loss in 2012 after the RXi spin-off, compared with a $1.641 million loss in Q3 2011. The nine-month 2012 discontinued-operations loss was $1.644 million versus $5.898 million.
Outlook, risks, contingencies, and unusual items
- Management expected existing cash and working capital to fund operations through at least the third quarter of 2013. The company anticipated continued significant losses and higher R&D spending, and said profitability might never be achieved.
- Further funding may be needed through equity, debt, research funding, partnerships, or collaborations. Galena warned that funding might not be available on acceptable terms or at all; without it, the company might need to scale back, terminate operations, or seek a merger or acquisition.
- The NeuVax acquisition carried up to $32 million in future development and commercial milestone consideration, payable at the company’s election in cash or shares. One milestone was settled with shares released from escrow in September 2012, plus approximately $35,000 in interest.
- Warrant and contingent-consideration liabilities are measured at fair value and can make reported earnings volatile. The nine-month warrant revaluation substantially increased reported loss despite being a non-cash adjustment.
- The company disclosed no legal proceedings, material subsequent events, or off-balance-sheet financing arrangements other than operating leases. Management reported effective disclosure controls and no material change in internal control over financial reporting.
Important facts for investors to verify
- Confirm the clinical progress, enrollment, timing, and outcomes of the NeuVax PRESENT trial and the other vaccine studies; this filing gives no trial-results update beyond stating that PRESENT was ongoing.
- Assess whether the stated cash runway remains adequate against clinical-trial spending and the need for additional financing.
- Review the assumptions and potential cash-or-share settlement effects behind the $4.904 million warrant liability and $6.791 million contingent consideration.
- Track dilution and capital needs, including common shares outstanding and potential issuance from options, warrants, and acquisition milestones.
- Consider the filing’s development-stage status and lack of revenue when evaluating prospects for commercialization and profitability.